PaperlayerView exact revision on arXiv

Source-linked AI summary

Empowering Biomedical Discovery with AI Agents

Shanghua Gao, Ada Fang, Yepeng Huang, Valentina Giunchiglia, Ayush Noori, Jonathan Richard Schwarz, Yasha Ektefaie, Jovana Kondic, Marinka Zitnik

arXiv:2404.02831v2cs.AI

TL;DR

Biomedical research needs systems that can reason, learn, and coordinate across heterogeneous data, tools, and experimental platforms without removing human expertise from discovery. The paper envisions collaborative biomedical AI agents that use LLMs, generative models, structured memory, and ML tools to plan and support research, while emphasizing safeguards, evaluation, data, and governance challenges. Their practical scope therefore depends on responsible deployment, human oversight, and reliable integration into biomedical workflows.

  • Problem

    Biomedical discovery requires systems that can reason and operate across diverse modalities, tools, and experimental settings while addressing limited datasets, reliability, safety, and evaluation challenges.

  • Method

    The paper proposes collaborative biomedical AI agents that combine LLMs, generative models, structured memory, ML tools, experimental platforms, and human experts.

  • Results

    The paper presents a vision in which biomedical AI agents support discovery workflows across virtual cells, phenotype control, cellular circuits, and therapies, with autonomy organized into levels including research-assistant agents.

  • Takeaways & Limitations

    Biomedical AI agents are positioned as research assistants and collaborators that extend human expertise through data analysis, hypothesis navigation, planning, and repetitive-task automation.

  • Takeaways & Limitations

    Increasing autonomy raises misuse and overreliance risks, while reproducibility, workflow standardization, large open datasets, safe deployment, and reliable reasoning remain unresolved.

Abstract

from arXiv · show

We envision "AI scientists" as systems capable of skeptical learning and reasoning that empower biomedical research through collaborative agents that integrate AI models and biomedical tools with experimental platforms. Rather than taking humans out of the discovery process, biomedical AI agents combine human creativity and expertise with AI's ability to analyze large datasets, navigate hypothesis spaces, and execute repetitive tasks. AI agents are poised to be proficient in various tasks, planning discovery workflows and performing self-assessment to identify and mitigate gaps in their knowledge. These agents use large language models and generative models to feature structured memory for continual learning and use machine learning tools to incorporate scientific knowledge, biological principles, and theories. AI agents can impact areas ranging from virtual cell simulation, programmable control of phenotypes, and the design of cellular circuits to developing new therapies.

Introduction

Biomedical AI agents are envisioned as collaborative systems that combine language models, machine-learning tools, experimental platforms, and human expertise to support discovery. They can decompose complex biological problems, automate research tasks, and operate across applications from virtual cells to therapy development, while requiring safeguards and human oversight.

  • Vision: AI agents coordinate LLMs, ML tools, experimental platforms, and humans through reflective learning and reasoning.They can decompose complex biological problems into specialized subtasks and integrate the resulting scientific knowledge.
  • Capabilities: Agents can accelerate discovery by automating repetitive processes, analyzing large datasets, and navigating hypothesis spaces at greater scale and precision.The passages describe continuous, high-throughput research that would be difficult for human researchers to perform alone.
  • Enabling technologies: Advances in LLMs, multimodal learning, and generative models support agent cooperation, feedback, critique, and identification of knowledge gaps.Chat-optimized LLMs can enable conversations among agents and with humans.
  • Applications: Biomedical AI agents may support virtual cell simulation, programmable phenotype control, cellular-circuit design, and development of new therapies.These applications include predicting cellular responses, guiding genetic edits, and optimizing genetic components.
  • Challenges: Biomedical agents require safeguards and human oversight because environmental actions can be dangerous and available experimental datasets remain limited across use cases.They also need data-efficient biomedical knowledge representation and strong generalization to new tasks.

Evolving use of data-driven models in biomedical research

Biomedical research has progressed from databases and search engines to machine-learning and interactive learning models, each adding capabilities while retaining important limitations. AI agents extend this trajectory by reasoning over information, refining searches, and interacting with tools, but existing interactive models remain narrow and difficult to generalize.

  • Databases and search engines: Databases and search engines aggregate and retrieve standardized biological information but do not reason over queries or iteratively refine results.Curated databases can reduce misinformation, yet they lack mechanisms to remove irrelevant information.
  • AI agents: AI agents formulate search queries, retrieve information when needed, and iteratively process passages to customize actions during inference.Retrieval-augmented generation supports answering questions from scientific literature.
  • Machine learning models: Machine-learning models identify patterns and generalize predictions about novel data, but typically require specialized models for individual tasks.They do not possess the reasoning and interactive capabilities that distinguish AI agents.
  • Interactive learning: Interactive learning incorporates exploration mechanisms and human feedback, helping build models when datasets are small or conventional ML lacks statistical power.Active learning selectively queries informative data.
  • Interactive learning: Interactive models have been applied to molecule and protein design, drug discovery, perturbation experiments, and cancer screening, but struggle to generalize without retraining.GENTRL, for example, uses reinforcement learning to navigate chemical space toward compounds acting against biological targets.

Types of biomedical AI agents

Biomedical AI agents can be organized as heterogeneous multi-agent systems that combine LLMs, machine-learning tools, specialized domain tools, and human experts. Proposed collaboration schemes range from idea generation and critique to iterative self-driving laboratories that test and refine hypotheses.

  • System architecture: The proposed multi-agent systems combine heterogeneous ML tools, domain-specific tools, and human experts rather than relying only on a single LLM.This broader design reflects that much biomedical research is not text-based.
  • Role assignment: Biological agent roles can be assigned through domain-specific fine-tuning, in-context learning, or automatically generated optimized roles.Fine-tuning can include biological task instruction tuning and RLHF, whereas in-context learning uses task-specific prompts and instructions.
  • Role assignment: Single LLM agents often lack the comprehensive skills needed for complex tasks because mimicry-based learning does not provide deep behavioral understanding.Multi-agent deployment is presented as a practical alternative.
  • Collaborative schemes: Brainstorming agents pool diverse specialist ideas, while expert-consultation, debate, and round-table schemes use feedback, contrasting evidence, or multiple viewpoints to refine decisions.The examples include specialized agents contributing complementary perspectives to Alzheimer’s research.
  • Collaborative schemes: Self-driving lab agents iteratively optimize discovery workflows by designing experiments, analyzing results, updating scientific knowledge, and refining hypotheses under broad scientific direction.The scheme includes hypothesis ranking by biomedical value and experimental cost, uncertainty analysis, and use of counterexamples.

Levels of autonomy in AI agents

The paper classifies biomedical AI agents by capabilities in hypothesis formation, experimentation, and reasoning, from tool-assisted systems to prospective scientist-like collaborators. Increasing autonomy broadens potential research scope while raising concerns about misuse and overreliance.

  • Classification framework: Biomedical AI agents are classified into four levels according to capabilities in Hypothesis, Experiment, and Reasoning, with the lowest capability across areas determining the overall level.An agent with Level 3 Experiment capabilities but Level 2 Hypothesis and Reasoning capabilities is classified as Level 2.
  • Levels 0–1: Level 0 uses machine-learning models as tools, whereas Level 1 agents execute scientist-defined tasks with restricted tools and multimodal data.Examples include AlphaFold-Multimer-assisted hypothesis formation, ChemCrow, and AutoBa.
  • Level 2: At Level 2, scientists and agents collaboratively refine hypotheses while agents undertake tasks for hypothesis testing using broader machine-learning and experimental tools.The paper states that Level 2 agents remain constrained in understanding scientific phenomena and generating innovative hypotheses.
  • Risks and boundaries: Greater autonomy increases the potential for misuse and scientists’ risk of overreliance on agents, motivating preventive measures and scrutiny of agentic research.The paper highlights risks involving hazardous or controlled substances, misleading claims, misinformation, reproducibility, and peer review.
  • Application examples: In cell biology, Level 3 agents would combine digital agents with high-throughput experimental platforms to identify knowledge gaps and simulate perturbations.The proposed hybrid virtual cell models integrate AI tools with experimental agents.
  • Level 3: Level 3 agents are envisioned as scientist-like systems that work with humans to address challenging questions and unlock experimental capabilities beyond established protocols.In chemical biology, examples include binder design for undruggable targets and probing molecular dynamics at longer timescales.

Roadmap for building AI agents

The proposed roadmap builds biomedical AI agents from modular perception, interaction, memory, and reasoning capabilities. These modules support adaptive tool use, human collaboration, retention of experimental knowledge, and increasingly complex scientific planning.

  • Core architecture: AI agents are compound systems whose perception, interaction, memory, and reasoning modules support engagement with humans and experimental environments.The modules implement distinct functionalities within the agent architecture.
  • Adaptive workflows: Unlike static Snakemake- and Docker-like workflows, AI agents can learn new tools, adapt workflows to scientist-specific instructions, and restructure pipelines.The paper proposes extending multimodal and multi-scale omics integration beyond established protocols.
  • Perception: Perception modules combine natural-language and multimodal processing to interpret biological workflows, users, and diverse experimental data streams.Examples include animal behavior, biosensors, genomics, proteomics, biochemical assays, and 3D culture systems.
  • Interaction: Interaction modules let agents communicate with scientists, other agents, tools, and equipment, including through natural-language function calling.Agents can select available tools and interface components from textual descriptions of scientists’ intentions.
  • Human collaboration: Human-agent interaction aligns scientific objectives through dialogue, human evaluation, reinforcement learning from human feedback, or direct preference optimization.Human insight can guide complex tasks, interpret ambiguous requests, and refine agents’ responsiveness to user needs.
  • Memory: Memory modules store and recall experimental information for complex tasks and adaptation, using long-term knowledge stores and short-term conversational or contextual memory.Long-term memory may be internal or external, while short-term memory supports in-context learning and multi-round dialogue.
  • Reasoning: Reasoning capabilities help agents plan experiments, make decisions about biological hypotheses, and compare multiple possible pathways before producing a plan.Multi-path approaches can evaluate candidate proteins, targets, and experiments for testing.

Challenges

Biomedical AI agents face reliability, evaluation, data, safety, governance, and oversight challenges that constrain responsible deployment. These challenges include unreliable predictions, limited experimental standardization, insufficient datasets, and risks from autonomous interaction with laboratory environments.

  • Robustness and reliability: Unreliable predictions, reasoning errors, systematic biases, planning failures, and overconfidence can undermine agents connected to tools or experimental platforms.The paper identifies hallucinations and poor awareness of knowledge gaps as additional deployment barriers.
  • Evaluation protocols: Evaluations must assess theoretical capability, practical workflow integration, ethics, regulatory compliance, and performance beyond accuracy.Model updates without notice threaten reproducibility, while API-specific benchmarks may not measure general real-world interaction.
  • Data and workflow constraints: Variable biomedical workflows and limited large, open, AI-ready datasets complicate generalization and evaluation across biological applications.Experimental protocols vary by cell line, dosage, and time point, while datasets differ in modality, quality, and volume.
  • Governance: Responsible adoption requires governance frameworks that balance innovation with accountability and define human oversight and regulatory standards.The paper advocates multidisciplinary institutions and broad international policies to reduce risks being outsourced to weakly regulated jurisdictions.
  • Risks and safeguards: Autonomous laboratory interaction can create safety hazards, making close human supervision, safeguards, and accountability necessary.The paper warns that equipment failures, insufficient maintenance, or misaligned agents could produce harmful substances or mishandle volatile materials.
  • Biomedical deployment challenges: Biomedical agents still struggle to distinguish correlation from causality, generate strong hypotheses, validate experiments, and interact safely with high-throughput platforms.The paper also notes limitations in unbiased datasets that capture biological variation.

Outlook

The outlook presents biomedical AI agents as collaborative systems combining LLMs, machine-learning tools, experimental platforms, and humans. Their development depends on continual interaction, self-assessment, robust evaluation, ethical grounding, error mitigation, and governance frameworks that preserve accountability.

  • Outlook: Biomedical AI agents are envisioned as systems combining LLMs, machine-learning tools, experimental platforms, and humans for reflective learning and reasoning.The paper frames current AI as assistive in low-stakes, narrow tasks and proposes agents as a path toward broader capabilities.
  • Outlook: Continual human-AI interaction and trustworthy sandboxes can support agents that plan discovery workflows, learn from mistakes, and identify knowledge gaps.The proposed workflows include machine-learning feedback loops for experiments and agent self-assessment.
  • Robustness and reliability: Reliable agents require diverse evaluation protocols and grounding in ethical guidelines, laboratory protocols, and safety guidance.These measures are intended to identify vulnerabilities and align behavior with human values and safety standards.
  • Error management: Error management should combine internal self-evaluation with external anomaly-detection and distribution-shift models using biomedical domain knowledge.Iterative interactions and adaptive reasoning are presented as ways to diagnose, localize, and mitigate errors.
  • Governance and responsible human-AI partnership: Multidisciplinary governance institutions can define ethical and technical standards, including requirements for human oversight and accountability.The paper recommends developing standards through broad international institutions while pursuing responsible human-AI partnerships.
Loading 2404.02831v2…